Shanghai CataX Biotechnology Co., Ltd. (CataX AI) has announced the completion of a RMB 40 million seed round, incubated and exclusively invested by Qiming Venture Partners. Founded in July 2026 and headquartered in Shanghai, the company is an agent-native innovative drug R&D enterprise whose core team brings together expertise in clinical medicine, cutting-edge AI research, and senior clinical development experience. Focusing on the clinical development end, the company uses agents as its technological foundation to build a new organizational paradigm called "Clinical-of-One," and plans to advance drug assets at relevant stages through clinical proof of concept. A relevant person in charge stated that agents serve as the infrastructure of the company's organization, enabling transactional work to be delegated to specialized agents while key decisions are reviewed by humans; project experience is accumulated for continuous reuse, thereby improving clinical R&D efficiency. A relevant person in charge at Qiming Venture Partners believes that clinical development is a high-value segment poised to be restructured by AI, and that this model represents one possibility for the next generation of clinical R&D organizations. This column also features several interview articles related to the biopharmaceutical track.
